Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check13 days agoChange DetectedUpdated the study site list with many new locations and institutions, and removed several previously listed sites. The total number of locations is now 264.SummaryDifference3%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedFallopian tube cancer was added to the Conditions list and a Genetic and Rare Diseases Information Center resource was linked in Resources. The page revision is updated to v3.4.2 from v3.4.1.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, which are minor UI/version changes not affecting study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedShow glossary was added; update-related items (Last Update Submitted that Met QC Criteria and Last Update Posted) are displayed, and the page revision updated to Revision: v3.4.0, while older labeling such as No FEAR Act data and the previous revision text were removed.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page metadata now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.